Vaccines and kids 2

COVID-19 Vaccine Requirements: Considerations for U.S. Clinical Trial Participants

Nov 03, 2021 | Katherine Waters, Victoria Thompson

As the COVID-19 response evolves, vaccine requirements, sometimes referred to as mandates, are increasingly being used as a tool to improve vaccine uptake. Vaccine requirements, especially when used in specific settings such as the workplace or healthcare facilities, are a long-standing and proven public health strategy for increasing vaccination coverage and decreasing the incidence of morbidity and mortality associated with vaccine-preventable diseases, such as COVID-19. One main way in which vaccine requirements are being utilized is through the Biden Administration’s COVID-19 action plan which outlines vaccination requirements for the following groups:

  • Employers with 100 or more employees are to require vaccination or ensure weekly negative tests for unvaccinated employees;
  • Healthcare workers at Medicare and Medicaid participating hospitals and health care facilities; and
  • Federal workers and contractors that do business with the federal government.

In addition to the COVID-19 vaccines that are authorized and recommended for use in the United States (Moderna, Pfizer, and Janssen), some individuals may have been vaccinated for COVID-19 through a clinical trial in which the vaccine has not yet been approved in the U.S. For the purposes of vaccine requirements, it’s important to understand how to determine if a person who has been vaccinated through one of these trials is considered fully vaccinated. To do so, the Centers for Disease and Control and Prevention (CDC) has issued interim guidance for those who have been vaccinated as part of a clinical trial for a COVID-19 vaccine that is not currently approved or authorized by the Food and Drug Administration (FDA). Current CDC guidance is below.

A person vaccinated against COVID-19 as part of a clinical trial in the U.S. is considered fully vaccinated:

  • Two weeks after receiving the full vaccination series AND
  • The vaccine given is confirmed to have been an active vaccine, not a placebo dose AND
    • The vaccine is listed for emergency use by the World Health Organization (currently the AstraZeneca COVID-19 vaccine meets these criteria) OR
    • The vaccine efficacy has been independently confirmed (currently the Novavax COVID-19 vaccine meets these criteria)

As always, please reference CDC and FDA for the most current information regarding which COVID-19 vaccines have been approved in the United States. For additional information and resources, please see the relevant links below.

Biden Administration’s COVID-19 action plan

Different COVID-19 Vaccines | CDC

COVID-19 Vaccines | FDA

Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

COVID-19 Workplace Safety: Guidance for Federal Contractors and Subcontractors


About Katherine Waters

More posts by Katherine Waters

About Victoria Thompson

Victoria Thompson is a Senior Program Analyst on the Immunization Team at NACCHO.

More posts by Victoria Thompson

Related Posts

Microsoft Teams image
  • Webinar
  • Healthcare-Associated Infections
  • ID Featured
  • Infection, Prevention, and Control

Webinar: Tools to Address Multi-drug Resistant Organisms...

In this webinar, attendees will have the opportunity to learn about the Council...

Jan 24, 2023 | Irene Halferty

Webinar: Tools to Address Multi-drug Resistant Organisms...

SDOH Project Logo V2
  • Funding Opportunity
  • Community Health
  • Performance Improvement
  • Social Determinants of Health

RFP: Improving Social Determinants of Health – Getting...

Building upon the results of Years 1 and 2 of the CDC’s Improving Social...

Jan 23, 2023 | Andrea Grenadier

RFP: Improving Social Determinants of Health – Getting...

I Stock 1202344480 1
  • Opioid Overdose Epidemic

The National Association of County and City Health...

The National Association of County and City Health Officials (NACCHO), along...

Jan 23, 2023

The National Association of County and City Health...

Outbreak Chart
  • Community Health
  • Infectious Disease
  • Opportunity

NACCHO Disease Outbreaks and Analytics Project Call for...

NACCHO is currently recruiting members for a community of practice focused on...

Jan 23, 2023 | NacchoVoice

NACCHO Disease Outbreaks and Analytics Project Call for...

Congress
  • Immunization

Inflation Reduction Act: Improving Adults Enrolled in...

In August 2022, the Biden Administration passed the Inflation Reduction Act...

Jan 17, 2023 | Victoria Thompson

Inflation Reduction Act: Improving Adults Enrolled in...

CIC Scholarship Canva Image
  • Funding Opportunity
  • Antibiotic Resistance
  • Community Health
  • Healthcare-Associated Infections

Scholarship Opportunity for Local Health Department...

Apply today! NACCHO is offering a scholarship opportunity for local health...

Jan 09, 2023 | Jaclyn Abramson

Scholarship Opportunity for Local Health Department...

PFL Banner 1
  • Tools & Resources
  • Community Health
  • Infection, Prevention, and Control
  • Infectious Disease

An Unexpected Outbreak, Part 2

This is the second of a two-part blog series presenting two fictional, but...

Dec 19, 2022 | Irene Halferty

An Unexpected Outbreak, Part 2

PFL Banner 2
  • Tools & Resources
  • Community Health
  • Infection, Prevention, and Control
  • Infectious Disease

An Unexpected Outbreak, Part 1

This is the first of a two-part blog series on infection prevention and control...

Dec 19, 2022 | Irene Halferty

An Unexpected Outbreak, Part 1

2 Year COVIN graphic
  • COVID-19
  • Immunization

NACCHO Recognizes Second Anniversary of First COVID-19...

NACCHO and leading partners recognize December 14, 2022 as the two-year...

Dec 15, 2022 | Nicholas Holmes

NACCHO Recognizes Second Anniversary of First COVID-19...

Back to Top